NRIX Stock Price, Nurix Therapeutics, Inc. Quote, Chart

Market Summary

USD13.75-0.38

Market Closed

-2.69%

NRIX Alerts

Big jump in Revenue (Y/Y)

Losses in recent quarter

NRIX Stock Price

View Fullscreen

NRIX RSI Chart

NRIX Valuation

Market Cap

675.8M

Price/Earnings (Trailing)

-4.67

Price/Sales (Trailing)

8.36

EV/EBITDA

-4.6

Price/Free Cashflow

-8.06

NRIX Price/Sales (Trailing)

NRIX Profitability

EBT Margin

-177.96%

Return on Equity

-85.77%

Return on Assets

-46.29%

Free Cashflow Yield

-12.41%

NRIX Fundamentals

NRIX Revenue

Revenue (TTM)

80.9M

Rev. Growth (Yr)

30.74%

Rev. Growth (Qtr)

9.41%

NRIX Earnings

Earnings (TTM)

-144.7M

Earnings Growth (Yr)

-1.93%

Earnings Growth (Qtr)

1.04%

Breaking Down NRIX Revenue

Last 7 days

-3.5%

Last 30 days

5.3%

Last 90 days

81.9%

Trailing 12 Months

36.1%

How does NRIX drawdown profile look like?

NRIX Financial Health

Current Ratio

2.86

NRIX Investor Care

Shares Dilution (1Y)

3.59%

Diluted EPS (TTM)

-2.66

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	80.9M	0	0	0
2023	41.7M	60.9M	68.6M	77.0M
2022	34.4M	38.7M	39.2M	38.6M
2021	20.0M	22.9M	29.0M	29.8M
2020	24.7M	19.5M	13.0M	17.8M
2019	0	0	0	31.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Nurix Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 16, 2024	van houte hans	sold	-68,222	10.0151	-6,812	chief financial officer
Jan 30, 2024	hansen gwenn	sold	-18,649	7.9902	-2,334	chief scientific officer
Jan 30, 2024	hansen gwenn	acquired	-	-	5,207	chief scientific officer
Jan 30, 2024	van houte hans	sold	-13,351	7.9902	-1,671	chief financial officer
Jan 30, 2024	ring christine	acquired	-	-	3,924	chief legal officer
Jan 30, 2024	van houte hans	acquired	-	-	4,886	chief financial officer
Jan 30, 2024	ring christine	sold	-14,062	7.9902	-1,760	chief legal officer
Dec 20, 2023	van houte hans	sold	-35,421	10.0031	-3,541	chief financial officer
Dec 19, 2023	van houte hans	sold	-109,093	10.003	-10,906	chief financial officer
Oct 31, 2023	ring christine	sold	-6,403	5.1974	-1,232	chief legal officer

Which funds bought or sold NRIX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-61.96	-19,000	23,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	57,288	240,332	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	sold off	-100	-1,042,370	-	-%
Apr 19, 2024	DENALI ADVISORS LLC	sold off	-100	-593,400	-	-%
Apr 18, 2024	ARK Investment Management LLC	reduced	-17.52	5,767,080	38,739,500	0.27%
Apr 18, 2024	WASATCH ADVISORS LP	reduced	-55.02	-10,197,100	18,180,300	0.10%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	sold off	-100	-10,505	-	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	28.26	135,044	298,337	0.01%
Apr 05, 2024	GAMMA Investing LLC	added	160	13,319	16,787	-%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	reduced	-18.79	203,789	1,504,120	-%

Are Funds Buying or Selling NRIX?

Are funds buying NRIX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NRIX

No. of Funds

Unveiling Nurix Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	deep track capital, lp	6.18%	2,997,830	SC 13G/A
Feb 14, 2024	price t rowe associates inc /md/	4.9%	2,391,866	SC 13G/A
Feb 14, 2024	redmile group, llc	9.9%	5,021,886	SC 13G/A
Feb 14, 2024	baker bros. advisors lp	9.99%	4,952,452	SC 13G/A
Feb 14, 2024	sands arthur t	5.4%	2,707,896	SC 13G
Feb 13, 2024	vanguard group inc	5.36%	2,598,097	SC 13G
Feb 09, 2024	wasatch advisors lp	-	0	SC 13G/A
Feb 09, 2024	morgan stanley	6.4%	3,099,198	SC 13G
Jan 29, 2024	ark investment management llc	6.59%	3,194,999	SC 13G
Jan 24, 2024	blackrock inc.	9.6%	4,643,736	SC 13G/A

Recent SEC filings of Nurix Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 12, 2024	424B5	Prospectus Filed
Apr 12, 2024	8-K	Current Report
Apr 11, 2024	424B5	Prospectus Filed
Apr 10, 2024	10-Q	Quarterly Report
Apr 10, 2024	8-K	Current Report
Apr 09, 2024	8-K	Current Report
Mar 27, 2024	DEF 14A	DEF 14A
Mar 27, 2024	DEFA14A	DEFA14A
Mar 27, 2024	ARS	ARS
Mar 11, 2024	8-K	Current Report

Peers (Alternatives to Nurix Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-0.30%	-28.67%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	8.14%	-4.26%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.4B	-	-13.93%	67.39%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.40%	-0.33%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-6.74%	-16.88%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

Nurix Therapeutics, Inc. News

Latest updates

Nurix Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	9.4%	16,585,000	15,159,000	18,467,000	30,676,000	12,685,000	6,783,000	10,791,000	11,432,000	9,621,000	7,396,000	10,252,000	7,091,000	5,011,000	6,689,000	4,085,000	4,182,000	2,864,000	1,862,000	10,580,000	9,439,000	9,234,000
Operating Expenses	2.2%	61,804,000	60,493,000	58,479,000	57,441,000	55,637,000	55,473,000	57,509,000	57,147,000	52,365,000	45,349,000	39,249,000	33,505,000	29,533,000	26,697,000	23,277,000	17,412,000	15,417,000	-	13,192,000	-	-
S&GA Expenses	-100.0%	-	10,780,000	10,623,000	11,678,000	9,821,000	9,367,000	9,748,000	9,654,000	9,228,000	8,818,000	8,343,000	7,511,000	6,530,000	6,251,500	4,338,000	3,270,000	2,450,000	-	2,184,000	-	-
R&D Expenses	0.6%	50,005,000	49,713,000	47,856,000	45,763,000	45,816,000	46,106,000	47,761,000	47,493,000	43,137,000	36,531,000	30,906,000	25,994,000	23,003,000	20,445,500	18,939,000	14,142,000	12,967,000	-	11,008,000	-	-
EBITDA Margin	5.0%	-1.68	-1.77	-2.50	-2.82	-4.14	-4.53	-4.25	-3.90	-3.85	-3.84	-3.33	-3.78	-	-	-	-	-	-	-	-	-
Income Taxes	-	90,000	-	-	-	-	-	-	-	-	45,500	-100,000	100,000	71,000	53,000	-	-20,587,000	11,000	-	10,000	-	-
Earnings Before Taxes	-Infinity%	-41,428,000	-	-	-	-40,733,000	-46,717,000	-45,709,000	-45,401,000	-42,533,000	-37,658,000	-28,958,000	-26,243,000	-24,204,000	-19,873,000	-18,517,000	-13,007,000	-12,380,000	-	-2,417,000	-	-
EBT Margin	4.8%	-1.78	-1.87	-2.60	-2.93	-4.28	-4.67	-4.37	-3.99	-3.94	-3.93	-3.42	-3.88	-	-	-	-	-	-	-	-	-
Net Income	1.0%	-41,518,000	-41,956,000	-36,982,000	-24,277,000	-40,733,000	-46,717,000	-45,709,000	-45,401,000	-42,533,000	-37,702,000	-28,835,000	-26,382,000	-24,275,000	-19,914,000	-18,517,000	7,580,000	-12,391,000	-13,519,000	-2,427,000	-3,068,000	-2,685,000
Net Income Margin	4.3%	-1.79	-1.87	-2.17	-2.58	-4.28	-4.67	-4.37	-3.99	-3.94	-3.94	-3.42	-3.89	-	-	-	-	-	-	-	-	-
Free Cashflow	-286.0%	-44,835,000	24,104,000	-43,592,000	-19,549,000	-50,729,000	-40,520,000	-49,726,000	-35,703,000	-46,102,000	-31,773,000	-31,837,000	-33,626,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-12.1%	313	356	308	351	370	417	459	394	438	477	493	518	397	396	412	44.00
Current Assets	-15.1%	251	296	268	290	288	318	355	307	280	311	358	396	311	298	364	39.00
Cash Equivalents	-8.8%	50.00	55.00	42.00	59.00	34.00	64.00	48.00	42.00	79.00	81.00	147	188	126	119	266	35.00
Net PPE	6.3%	18.00	17.00	17.00	18.00	18.00	17.00	17.00	16.00	14.00	11.00	10.00	8.00	7.00	7.00	7.00	4.00
Liabilities	-7.2%	144	155	74.00	91.00	96.00	113	117	128	132	134	118	120	127	106	104	54.00
Current Liabilities	0.8%	88.00	87.00	61.00	72.00	65.00	71.00	68.00	73.00	66.00	66.00	51.00	47.00	48.00	45.00	41.00	16.00
Shareholder's Equity	-15.8%	169	200	234	260	274	304	343	267	306	342	375	398	270	290	308	-
Retained Earnings	-7.6%	-586	-545	-503	-466	-442	-401	-354	-308	-263	-220	-183	-154	-127	-103	-83.78	-60.46
Additional Paid-In Capital	1.3%	756	746	738	728	719	709	701	579	571	564	558	552	398	394	391	3.00
Shares Outstanding	0.9%	49.00	49.00	49.00	48.00	47.00	47.00	47.00	45.00	45.00	45.00	42.00	41.00	-	-	-	-
Float	-	-	-	-	471	-	-	-	444	-	-	-	1,100	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	-257.2%	-41,951	26,689	-41,133	-18,469	-48,452	-37,955	-46,308	-32,914	-42,630	-30,911	-29,972	-31,535	8,053	-20,482	-6,141	-14,429	40,972	-	-
Share Based Compensation	-2.5%	7,822	8,024	8,445	8,723	8,481	8,297	6,988	6,775	6,071	4,843	4,313	3,944	2,700	2,536	1,115	474	176	-	-
Cashflow From Investing	347.1%	35,513	-14,373	22,775	43,831	16,068	55,008	-63,076	-4,765	40,031	-36,523	-12,231	-57,110	-2,387	-124,563	-108,081	-2,336	-19,424	-	-
Cashflow From Financing	23100.0%	1,624	7.00	1,704	25.00	1,481	-135	115,407	432	1,488	500	1,552	150,471	1,359	-1,126	220,420	119,684	46.00	-	-

NRIX Income Statement

2024-02-29

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended
	Feb. 29, 2024	Feb. 28, 2023
Income Statement [Abstract]
Collaboration revenue and total revenue	$ 16,585,000	$ 12,685,000
Operating expenses:
Research and development	50,005,000	45,816,000
General and administrative	11,799,000	9,821,000
Total operating expenses	61,804,000	55,637,000
Loss from operations	(45,219,000)	(42,952,000)
Interest and other income, net	3,791,000	2,219,000
Loss before income taxes	(41,428,000)	(40,733,000)
Provision for income taxes	90,000	0
Net loss	$ (41,518,000)	$ (40,733,000)
Net loss per share, basic (in USD per share)	$ (0.76)	$ (0.75)
Net loss per share, diluted (in USD per share)	$ (0.76)	$ (0.75)
Weighted-average number of shares outstanding, basic (in shares)	54,903,407	54,028,238
Weighted-average number of shares outstanding, diluted (in shares)	54,903,407	54,028,238

NRIX Balance Sheet

2024-02-29

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Feb. 29, 2024	Nov. 30, 2023
Current assets:
Cash and cash equivalents	$ 49,813	$ 54,627
Marketable securities, current	194,180	233,281
Prepaid expenses and other current assets	6,976	7,595
Total current assets	250,969	295,503
Marketable securities, non‑current	10,292	7,421
Operating lease right-of-use assets	29,299	31,142
Property and equipment, net	17,871	16,808
Restricted cash	901	901
Other assets	3,342	3,823
Total assets	312,674	355,598
Current liabilities:
Accounts payable	5,918	6,401
Accrued expenses and other current liabilities	28,318	24,970
Operating lease liabilities, current	7,310	7,489
Deferred revenue, current	46,077	48,098
Total current liabilities	87,623	86,958
Operating lease liabilities, net of current portion	21,846	23,125
Deferred revenue, net of current portion	34,457	45,022
Total liabilities	143,926	155,105
Commitments and contingencies (Note 6)
Stockholdersʼ equity:
Preferred stock, $0.001 par value— 10,000,000 shares authorized as of February 29, 2024 and November 30, 2023; no shares issued and outstanding as of February 29, 2024 and November 30, 2023	0	0
Common stock, $0.001 par value— 500,000,000 shares authorized as of February 29, 2024 and November 30, 2023; 49,136,954 and 48,718,552 shares issued and outstanding as of February 29, 2024 and November 30, 2023, respectively	49	49
Additional paid-in capital	755,767	746,299
Accumulated other comprehensive loss	(350)	(655)
Accumulated deficit	(586,718)	(545,200)
Total stockholdersʼ equity	168,748	200,493
Total liabilities and stockholdersʼ equity	$ 312,674	$ 355,598

About Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255, a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences, Inc. to discover, develop, and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

CEO	Dr. Arthur T. Sands M.D., Ph.D.
WEBSITE	nurixtx.com
INDUSTRY	Biotechnology
EMPLOYEES	297

Nurix Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Nurix Therapeutics, Inc.? What does NRIX stand for in stocks?

NRIX is the stock ticker symbol of Nurix Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nurix Therapeutics, Inc. (NRIX)?

As of Tue Apr 23 2024, market cap of Nurix Therapeutics, Inc. is 694.5 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NRIX stock?

You can check NRIX's fair value in chart for subscribers.

What is the fair value of NRIX stock?

You can check NRIX's fair value in chart for subscribers. The fair value of Nurix Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Nurix Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NRIX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Nurix Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether NRIX is over valued or under valued. Whether Nurix Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Nurix Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NRIX.

What is Nurix Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, NRIX's PE ratio (Price to Earnings) is -4.8 and Price to Sales (PS) ratio is 8.59. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NRIX PE ratio will change depending on the future growth rate expectations of investors.